1105059-09-3

Basic information

• Product Name: 3-(2,4-bis(trifluoromethyl)phenyl)-5-((2-bromo-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)isoxazole
• Synonyms: 3-(2,4-bis(trifluoromethyl)phenyl)-5-((2-bromo-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)isoxazole
• CAS NO: 1105059-09-3
• Molecular Weight: 492.178
• Mol File: 1105059-09-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(2,4-bis(trifluoromethyl)phenyl)-5-((2-bromo-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,4-bis(trifluoromethyl)phenyl)-5-((2-bromo-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)isoxazole(1105059-09-3)
• EPA Substance Registry System: 3-(2,4-bis(trifluoromethyl)phenyl)-5-((2-bromo-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)isoxazole(1105059-09-3)

Safety Data

• Hazardous Substances Data: 1105059-09-3(Hazardous Substances Data)

Upstream product

• 858938-92-8 3-(2,4-(bis-trifluoromethyl)phenyl)-5-(chloromethyl)isoxazole 
• 1105059-07-1 2-bromo-5H-imidazo[4,5-d]pyridazine 
• 59664-42-5 2,4-bis(trifluoromethyl)benzaldehyde 
• 50847-09-1 2-bromo-1H-imidazole-4,5-dicarbonitrile 
• 1494717-93-9 2-bromo-1H-imidazo[4,5-d]pyridazine 
• 858938-91-7 2,4-bis(trifluoromethyl)benzaldehyde oxime 

Downstream Products

• 1105062-90-5 {5-[3-(2,4-bis-trifluoromethyl-phenyl)-isoxazol-5-ylmethyl]-5H-imidazo[4,5-d]pyridazin-2-yl}-phenyl-amine 
• 1105059-08-2 2-{5-[3-(2,4-bis-trifluoromethyl-phenyl)-isoxazol-5-ylmethyl]-5H-imidazo[4,5-d]pyridazine-2-yl}-phenylamine 
• 1105059-61-7 3-(2,4-bis(trifluoromethyl)phenyl)-5-((2-(2,6-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)methyl)isoxazole 

Relevant articles and documents

Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism

By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this e

ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. (I)